UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): January 25, 2006
ImmunoGen,
Inc.
(Exact
name of registrant as specified in its charter)
|
Massachusetts
|
0-17999
|
04-2726691
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
128
Sidney Street, Cambridge, MA 02139
(Address
of principal executive offices) (Zip Code)
Registrant's
telephone number, including area code: (617) 995-2500
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
8.01 - OTHER EVENTS
On
January 25, 2006, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) notified
ImmunoGen, Inc. (Nasdaq: IMGN) that as
part of
its ongoing portfolio management process and based on the evaluation of recent
clinical data in the context of other opportunities in its pipeline, Millennium
had decided not to continue the development of its MLN2704 compound. MLN2704
consists of a Millennium antibody to the Prostate-Specific Membrane Antigen
(PSMA) and ImmunoGen’s DM1 and was in development by Millennium under a 2001
agreement that gave Millennium rights to use ImmunoGen’s maytansinoid
Tumor-Activated Prodrug (TAP) technology with antibodies targeting PSMA. On
January 26, 2006, Millennium publicly disclosed that it had discontinued
development of MLN2704 and that it was in the process of evaluating whether
to
continue development of this antibody conjugated with other cell-killing agents
including other maytansanoids. Millennium retains its right to use ImmunoGen’s
maytansinoid TAP technology with antibodies targeting PSMA.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
ImmunoGen,
Inc.
|
|
|
(Registrant)
|
|
|
|
|
Date:
January 26, 2006
|
/s/
Karleen M. Oberton
|
|
|
|
|
|
Karleen
M. Oberton
|
|
|
Senior
Corporate Controller
|
|
|
(Principal
Accounting Officer)
|
3